Head-To-Head Review: Phio Pharmaceuticals (NASDAQ:PHIO) and Clearmind Medicine (NASDAQ:CMND)

Clearmind Medicine (NASDAQ:CMND) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, institutional ownership, profitability, analyst recommendations and valuation.

Insider and Institutional Ownership

96.1% of Clearmind Medicine shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 0.6% of Phio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for Clearmind Medicine and Phio Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clearmind Medicine	0	0	0	0	N/A
Phio Pharmaceuticals	0	0	1	0	3.00

Phio Pharmaceuticals has a consensus target price of $36.00, suggesting a potential upside of 1,190.32%. Given Phio Pharmaceuticals’ higher possible upside, analysts plainly believe Phio Pharmaceuticals is more favorable than Clearmind Medicine.

Valuation & Earnings

This table compares Clearmind Medicine and Phio Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clearmind Medicine	N/A	N/A	-$8.62 million	N/A	N/A
Phio Pharmaceuticals	N/A	N/A	-$10.83 million	($29.25)	-0.10

Profitability

This table compares Clearmind Medicine and Phio Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clearmind Medicine	N/A	-205.13%	-94.22%
Phio Pharmaceuticals	N/A	-142.68%	-111.75%

Volatility and Risk

Clearmind Medicine has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.

About Clearmind Medicine

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.